News | July 02, 2012

Six-minute Walk Stress Echo is Practical, Cost-effective to Evaluate Patients With Connective Tissue Disease

July 2, 2012 — Researchers have announced the results of a study that shows the utility of a six minute walk stress echocardiogram for the early detection of exercise-induced pulmonary arterial hypertension (EIPAH) in patients with connective tissue disease (CTD). Earlier treatment of these patients may improve the prognosis for CTD, as those who develop EIPAH may be at risk for resting pulmonary arterial hypertension (PAH) in the future.

A poster based on the study will be presented on Sunday, July 1 from 9:30 a.m. to 4:30 p.m. in the exhibit and poster hall during the American Society of Echocardiography (ASE) 23rd Annual Scientific Sessions. Investigators will be available in the hall from 12:15 p.m. to 1:45 p.m. The ASE Scientific Sessions will be held from June 27 to July 3, 2012, at the Gaylord National in National Harbor, MD.

“Doppler echocardiography is currently the recommended screening modality to diagnose PAH; however, in about two-thirds of cases, the pulmonary vascular bed had been already impaired in patients diagnosed to have PAH at rest. To diagnose PAH earlier, it is helpful to detect exercise-induced PAH (EIPAH) by stress echocardiography. Our study shows the efficacy of 6-minute walk stress echocardiography for this purpose. In our study, we were able to detect EIPAH in CTD patients who did not have PAH when at rest. Six-minute walk stress echocardiography is an easy, inexpensive and useful tool for detecting EIPAH, which could be very early-stage PAH,” said primary investigator Junko Hotchi.

Hirotsugu Yamada, Susumu Nishio, Noriko Tomita, Shuji Hayashi, Mika Bando, Rina Tamai, Maya Nakagawa, Daichi Hirota, Yukina Hirata, Kozue Ogasawara, Sachiko Bando, Takayuki Ise, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, and Masataka Sata, all of Tokushima University Hospital, Tokushima, Japan, and Kenya Kusunose of the Cleveland Clinic, Cleveland, were also part of the team that conducted the study, which found EIPAH in 29 out of a 109 patient study group.

For more information: www.asecho.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init